Rhenman & Partners Asset Management Ab Neurocrine Biosciences Inc Transaction History

Rhenman & Partners Asset Management Ab

$1.01 Billion
Q2 2024

A detailed history of Rhenman & Partners Asset Management Ab transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 75,555 shares of NBIX stock, worth $9.09 Million. This represents 1.03% of its overall portfolio holdings.

Number of Shares

75,555

Previous 59,000 28.06%

Holding current value

$9.09 Million

Previous $8.14 Million 27.82%

% of portfolio

1.03%

Previous 0.8%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$130.86 - $143.19 $2.17 Million - $2.37 Million	16,555 Added 28.06%	75,555 $10.4 Million
Q1 2024 May 14, 2024	SELL	$130.4 - $143.74 $391,200 - $431,220	-3,000 Reduced 4.84%	59,000 $8.14 Million
Q4 2023 Feb 13, 2024	BUY	$106.07 - $132.76 $788,524 - $986,937	7,434 Added 13.62%	62,000 $8.17 Million
Q3 2023 Nov 13, 2023	BUY	$94.02 - $117.1 $1.37 Million - $1.71 Million	14,566 Added 36.42%	54,566 $6.14 Million
Q2 2023 Aug 11, 2023	SELL	$89.53 - $104.87 $2.69 Million - $3.15 Million	-30,000 Reduced 42.86%	40,000 $3.77 Million
Q1 2023 May 11, 2023	SELL	$94.11 - $123.02 $1.41 Million - $1.85 Million	-15,000 Reduced 17.65%	70,000 $7.09 Million
Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $213,440 - $254,120	2,000 Added 2.41%	85,000 $10.2 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $1.1 Million - $1.29 Million	-12,000 Reduced 12.63%	83,000 $9.56 Million
Q2 2022 Aug 12, 2022	SELL	$75.79 - $100.07 $757,900 - $1 Million	-10,000 Reduced 9.52%	95,000 $9.26 Million
Q1 2022 May 13, 2022	SELL	$72.45 - $94.81 $3.34 Million - $4.37 Million	-46,100 Reduced 30.51%	105,000 $9.84 Million
Q4 2021 Feb 11, 2022	BUY	$79.65 - $106.22 $4.47 Million - $5.96 Million	56,100 Added 59.05%	151,100 $12.8 Million
Q3 2021 Nov 12, 2021	SELL	$86.18 - $99.03 $861,800 - $990,300	-10,000 Reduced 9.52%	95,000 $9.11 Million
Q2 2021 Aug 13, 2021	SELL	$89.43 - $102.27 $4.47 Million - $5.11 Million	-50,000 Reduced 32.26%	105,000 $10.2 Million
Q1 2021 May 14, 2021	BUY	$87.57 - $119.4 $437,849 - $597,000	5,000 Added 3.33%	155,000 $15.1 Million
Q4 2020 Jan 19, 2021	BUY	$86.91 - $108.33 $6.52 Million - $8.12 Million	75,000 Added 100.0%	150,000 $14.4 Million
Q2 2020 Jul 16, 2020	SELL	$85.09 - $130.36 $4.68 Million - $7.17 Million	-55,000 Reduced 42.31%	75,000 $9.15 Million
Q1 2020 Apr 16, 2020	BUY	$75.11 - $113.76 $751,100 - $1.14 Million	10,000 Added 8.33%	130,000 $11.3 Million
Q4 2019 Jan 17, 2020	SELL	$86.8 - $118.57 $2.57 Million - $3.51 Million	-29,600 Reduced 19.79%	120,000 $12.9 Million
Q3 2019 Oct 16, 2019	SELL	$83.82 - $101.5 $2.55 Million - $3.09 Million	-30,400 Reduced 16.89%	149,600 $13.5 Million
Q2 2019 Jul 22, 2019	BUY	$72.24 - $91.27 $210,146 - $265,504	2,909 Added 1.64%	180,000 $15.2 Million
Q1 2019 Apr 11, 2019	SELL	$69.31 - $91.53 $1.66 Million - $2.2 Million	-24,000 Reduced 11.93%	177,091 $15.6 Million
Q4 2018 Feb 05, 2019	BUY	$68.32 - $124.36 $8.16 Million - $14.9 Million	119,414 Added 146.2%	201,091 $14.4 Million
Q3 2018 Oct 03, 2018	SELL	$98.88 - $125.85 $2.84 Million - $3.61 Million	-28,700 Reduced 26.0%	81,677 $10 Million
Q2 2018 Jul 20, 2018	BUY	$75.3 - $105.99 $28,388 - $39,958	377 Added 0.34%	110,377 $10.8 Million
Q1 2018 Apr 11, 2018	SELL	$75.88 - $92.43 $604,687 - $736,574	-7,969 Reduced 6.76%	110,000 $9.12 Million
Q4 2017 Jan 19, 2018	BUY	$58.53 - $77.59 $173,775 - $230,364	2,969 Added 2.58%	117,969 $9.15 Million
Q3 2017 Oct 13, 2017	BUY	$47.97 - $61.28 $5.52 Million - $7.05 Million	115,000	115,000 $7.05 Million

Others Institutions Holding NBIX

# of Institutions

622

Shares Held

95.2M

Call Options Held

661K

Put Options Held

221K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.5B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account

Rhenman & Partners Asset Management Ab Neurocrine Biosciences Inc Transaction History